Organon (OGN) Non-Current Assets (2020 - 2026)
Organon (OGN) posted quarterly Non-Current Assets of $8.1 billion for Q2 2026, down 9.18% year-over-year from $8.9 billion in Q2 2025, and little changed on a QoQ basis from $8.1 billion in Q1 2026.
Organon (OGN) Non-Current Assets (2020 - 2026) Analysis & Trends
Organon has reported Non-Current Assets for 7 years, with the latest figure at $8.1 billion in Q2 2026.
- Non-Current Assets for Q2 2026 came in at $8.1 billion, down 9.18% year-over-year; the trailing twelve-month figure through Jun 2026 was $33.5 billion (down 2.67% YoY), and the FY2025 annual result was $8.5 billion, down 2.72% from the prior year.
- Non-Current Assets held at $8.1 billion in Q2 2026, from $8.1 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.9 billion in Q2 2025 and troughed at $6.8 billion in Q2 2022.
- A 5-year average of $7.7 billion and a median of $7.7 billion in 2024 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2025, when Non-Current Assets advanced 16.18%; it then declined 9.18% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $7.0 billion in 2022, then rose by 7.49% to $7.6 billion in 2023, then grew by 15.93% to $8.8 billion in 2024, then fell by 2.72% to $8.5 billion in 2025, then slipped by 5.26% to $8.1 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $8.1 billion in Q2 2026, $8.1 billion in Q1 2026, and $8.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Bn |
| Mar 31, 2026 | 8.06 Bn |
| Dec 31, 2025 | 8.52 Bn |
| Sep 30, 2025 | 8.85 Bn |
| Jun 30, 2025 | 8.88 Bn |
| Mar 31, 2025 | 8.79 Bn |
| Dec 31, 2024 | 8.75 Bn |
| Sep 30, 2024 | 8.00 Bn |
| Jun 30, 2024 | 7.65 Bn |
| Mar 31, 2024 | 7.70 Bn |
| Dec 31, 2023 | 7.55 Bn |
| Sep 30, 2023 | 6.96 Bn |
| Jun 30, 2023 | 7.02 Bn |
| Mar 31, 2023 | 6.98 Bn |
| Dec 31, 2022 | 7.02 Bn |
| Sep 30, 2022 | 6.85 Bn |
| Jun 30, 2022 | 6.84 Bn |
| Mar 31, 2022 | 6.88 Bn |
| Dec 31, 2021 | 6.92 Bn |
| Sep 30, 2021 | 7.01 Bn |